Full Picture

Extension usage examples:

Here's how our browser extension sees the article:
Appears well balanced

Article summary:

1. The NANOM-FIM trial is a long-term study of the safety and efficacy of plasma photothermal therapy using nanoscale particles for treating arterial sclerosis.

2. The research was conducted by members of the NANOM-FIM trial consortium, including the Ural Institute of Cardiology, Ural Medical University, Ural Federal University's Ural Modern Nanotechnology Center, and CoreLab Clinic.

3. The authors thank the European Commission FP2013-IIF Marie Curie Individual Fellowship Program for supporting the DREAM project which developed bioresorbable stents and nanotechnologies to reverse arterial sclerosis.

Article analysis:

The article is generally trustworthy and reliable in its reporting on the NANOM-FIM trial. It provides detailed information about the research team involved in conducting the trial, as well as their affiliations and contributions to the project. It also acknowledges funding from the European Commission FP2013-IIF Marie Curie Individual Fellowship Program for supporting DREAM, which developed bioresorbable stents and nanotechnologies to reverse arterial sclerosis. The article does not appear to be biased or one-sided in its reporting; it presents both sides equally and does not make unsupported claims or omit any points of consideration or evidence for its claims. Furthermore, it does not contain any promotional content or partiality towards any particular side or opinion. Finally, it notes possible risks associated with plasma photothermal therapy using nanoscale particles for treating arterial sclerosis, thus providing readers with a balanced view of this treatment option.